Neurocrine nears $2.5bn-plus deal for biotech behind obesity disorder treatment - Financial Times
Source:Financial Times
Soleno Therapeutics makes first commercialised drug for extreme hunger caused by Prader-Willi syndrome
Related Articles
Warren Buffett Sells Stocks in His Final Quarter as Berkshire Hathaway CEO: Should You Follow Suit? - GOBankingRates
In the fourth quarter of 2025, Warren Buffett’s last as the CEO of Berkshire Hathaway, the …
With caviar McNuggets and heart-shaped pizza, fast food chains hope to win Valentine's diners - AP News
It’s a tale as old as time, or at least as old as TikTok: chicken nuggets lovingly topped with a dab …
FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide - Johnson & Johnson
Johnson & Johnson introduces the first and only IL-23R targeted oral peptide that delivers …
Nio deliveries double in Jan, buoyed by strong performance of ES8 SUV - CnEVPost
Nio delivered 27,182 vehicles in January, marking a 96.08% year-on-year increase, though down 43.53% …